Jun. 24 at 11:50 PM
$ENVB $PLSM $CUPR $CDT
ENVB: next 100% Runner
Enveric Biosciences (NASDAQ: ENVB) operates with zero total debt and roughly
$4.91M in cash.
ENVB shares surged significantly (upwards of 140% to 160% in a single session) on news that the FDA was instructed to cut red tape around psychedelic drug approvals.Fast-Tracking Therapies: The directive directed the FDA to issue vouchers that could potentially cut the standard drug review time from 6-10 months down to 1-2 months.